AMGEN INC (AMGN)

US0311621009 - Common Stock

316.91  -2.31 (-0.72%)

After market: 317.1 +0.19 (+0.06%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AMGEN INC

NASDAQ:AMGN (11/4/2024, 8:00:00 PM)

After market: 317.1 +0.19 (+0.06%)

316.91

-2.31 (-0.72%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month2.18%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap170.35B
Shares
PE16.49
Fwd PE15.05
Dividend Yield2.82%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMGN Daily chart

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 26,700 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. The company operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Company Info

AMGEN INC

One Amgen Center Drive

Thousand Oaks CALIFORNIA 91320

P: 18054471000

CEO: Robert A. Bradway

Employees: 26700

Website: https://www.amgen.com/

AMGN News

News Image4 days ago - Investor's Business DailyStock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review

The major indexes declined, but haven't fallen apart.

News Image5 days ago - The Motley FoolAmgen (AMGN) Q3 2024 Earnings Call Transcript

AMGN earnings call for the period ending September 30, 2024.

News Image5 days ago - Investor's Business DailyAmgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO

The company expects to have topline results from a Phase 2 study later this year.

News Image5 days ago - BloombergAmgen’s Profit Beats Expectations on Lower Than Estimated Costs

Amgen Inc.’s third-quarter profit beat Wall Street estimates as the company’s expenses were lower than anticipated.

News Image5 days ago - AmgenAMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects...

News Image5 days ago - Market News VideoNotable Wednesday Option Activity: HIMS, UAL, AMGN

AMGN Twits

Here you can normally see the latest stock twits on AMGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example